Pipeline

Topelia is committed to initially advancing the development of TPL101 to fight COVID-19 infections.

Given its mechanism of action, which targets proteins conserved across various viruses, Topelia plans to investigate TPL101’s effectiveness against other respiratory viral infections, including Avian influenza and diseases caused by the Flaviviridae family (such as Dengue, Zika, and Yellow Fever).